Rystiggo
Rystiggo ingredients
| Active ingredient | Strength |
|---|---|
| Rozanolixizumab | 140 mg/mL |
What Rystiggo is used for
The FDA lists the approved uses on the official label (below). In the EU, rozanolixizumab is approved as Rystiggo for:
Rystiggo is indicated as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Rystiggo
- Generic name
- Rozanolixizumab
- Made by
- UCB, Inc.
- Forms
- Injection, Solution
- Given
- Subcutaneous
- Drug class
- Neonatal Fc Receptor Blocker
- FDA approval
- Biologic licence (BLA) BLA761286
- On the US market since
- 2023
Official information
- MedlinePlus drug information (search for Rozanolixizumab)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Rystiggo?
Rystiggo (Rozanolixizumab) is a specialist medicine made by UCB, Inc., approved by the US FDA.
What are the ingredients of Rystiggo?
Rystiggo contains Rozanolixizumab (140 mg/mL).
Is Rystiggo approved in Europe?
The same active substance is approved in the EU as Rystiggo.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA